Detecting cancer early is very important to help patients do better. When cancer is found early, treatments usually work better and patients have a higher chance to survive. Companies like Caris Life Sciences and Labcorp Oncology provide tests that help find cancer early and accurately. These tests use not only traditional biopsy methods but also new blood tests, called liquid biopsies, that find markers from tumors in the blood.
Caris Life Sciences uses a blood test called Caris Assure®. This test reads molecular information from a simple blood sample using circulating nucleic acid sequencing (cNAS). This means testing is less painful and can be done more often. This is helpful in the United States where cutting down hospital visits and painful procedures saves money and makes patients more comfortable.
Labcorp Oncology offers tests that check for different cancer markers like KRAS, HER2, PD-L1, and EGFR. These markers help doctors spot cancer early and decide on the right treatment. Labcorp also supports clinical trials with nurses who visit patients at home and has many patient service centers. This helps people in rural or hard-to-reach areas get tested and treated, which is important for fair healthcare access in the U.S.
After cancer is found, the next step is choosing the best treatment. Today, treatment is often based on the specific genetic makeup of each person’s tumor. Caris Life Sciences leads in this area by combining molecular science and artificial intelligence (AI) to study DNA, RNA, and proteins in tumor cells. Their MI Profile® test looks at more than 23,000 genes using whole exome sequencing (WES), whole transcriptome sequencing (WTS), and protein tests.
This detailed testing helps doctors learn exactly how each tumor behaves and pick treatments that fit best. For example, Caris studies over 38 billion molecular markers from more than 6.5 million tests to help choose treatments based on gene mutations, gene activity, and protein markers. This careful study can improve the chances that the treatment will work.
Labcorp Oncology also offers tests for important cancer markers used to decide on treatments. These include KRAS for colorectal cancer, HER2 for breast cancer, PD-L1 for immune treatments, and others. US cancer care is moving toward using these test results quickly in clinical settings. This helps start the right treatment sooner and avoids trying many treatments that might not work.
The last step in cancer care is watching how well treatment is working. Cancer can change or become resistant, so doctors need to check often and change treatments if needed. Blood tests and tissue tests can show how the tumor responds in real time.
Caris Life Sciences watches patients with their molecular tests and AI tools that predict how a patient might respond using both molecular data and clinical records. They have over 580,000 patient records linking molecular and clinical information, which helps doctors understand what to do next. Monitoring helps catch problems early, so doctors can switch treatments or add support care sooner.
Caris has also digitized about 4.5 million pathology slides to combine microscope images with molecular data. This gives a full picture of cancer’s progress. Labcorp supports continuous monitoring by providing long-term biomarker tests and home care services, making it easier for patients to stay involved without too much travel.
Artificial intelligence (AI) is very useful for handling the huge amount of data from cancer care. Caris Life Sciences uses AI and machine learning to study over 13 quadrillion data points from molecular and clinical information. AI helps classify cancers by their molecular traits and predict how patients will respond to treatment faster and more accurately than older methods.
The AI provides over 220 different predictions from complex data. These help doctors make better treatment decisions based on each patient’s unique molecular profile. This is especially helpful in U.S. healthcare, where fast decisions can improve care and lower costs.
Caris Molecular AI looks beyond fixed genetic markers and uses data that changes as new patient results and studies come in. This keeps treatment guidelines up to date with new science and patient experiences.
For clinic managers, owners, and IT workers, AI also helps in running a medical office smoothly. Automation tools help with patient messages, booking appointments, and sending test results. This reduces the amount of work on staff, keeps patients informed, and helps patients follow their testing and treatment schedules.
Companies like Simbo AI offer phone systems powered by AI that answer calls and book appointments using natural language. These systems reduce human mistakes and save time. In cancer care, where quick communication about test results and treatment changes matters, this lets staff focus more on patient care.
IT teams also need to handle large data safely and reliably. AI must work with electronic health records (EHR) so labs, doctors, and office staff can share information easily. Automated alerts for important lab results or treatment updates help doctors respond faster.
Because more patients want personalized cancer care, combining AI diagnostics with office automation creates a workflow that is efficient and patient-friendly. This helps patients stay happier and improves health results by cutting delays and avoiding mistakes in communication.
Using advanced molecular tests and AI support helps cancer care work better in medical offices across the U.S. Practice leaders should know about these technologies to make care better and manage patients well. Big databases like Caris Life Sciences’ help pick treatments more accurately, which might save money by avoiding treatments that don’t work.
Medical offices must also plan for technology needs and train their staff to use these new tools. Labcorp Oncology’s model of giving tests at home or closer to where people live shows a way for rural and underserved people to get better cancer care services.
Patients also gain from connected tests and constant monitoring. For example, Diane Davis, who survived ovarian cancer, says molecular testing helped doctors find the best treatment plan that worked for her.
Cancer care in the U.S. can improve by combining advanced molecular diagnostics, AI tools, and workflow automation. These parts support complete care from early detection through treatment choice and ongoing monitoring. This leads to better patient results and smoother clinic operations.
Caris Life Sciences aims to help improve the lives of individuals by utilizing transformative technologies informed by extensive data to advance precision medicine and enhance patient outcomes.
Caris provides physicians with comprehensive molecular information derived from genomic, transcriptomic, and proteomic data, enabling them to make informed, individualized treatment decisions for their patients.
Caris maintains one of the largest multimodal databases of molecular and clinical outcomes data, consisting of over 580,000 matched patient records.
Molecular profiling allows doctors to pinpoint effective treatments tailored to the individual genetic makeup of a patient’s cancer, leading to improved treatment success.
AI plays a crucial role in Caris by enhancing bioinformatics and machine learning capabilities to analyze massive datasets, classifying cancer molecularly, and predicting patient responses.
Caris offers services that cover the full care continuum, including disease detection, therapy selection, and treatment monitoring, ensuring comprehensive care for cancer patients.
Caris Molecular AI leverages a significant database to create novel solutions for classifying cancer and predicting treatment responses using advanced machine learning techniques.
Caris offers blood-based and tissue-based testing, including whole exome and transcriptome sequencing, to generate insights into a patient’s unique molecular profile.
Early disease detection enhances the chances of successful treatment by identifying cancer at a stage when it is more manageable and treatable.
Caris has processed over 6.5 million tests, measured over 38 billion molecular markers, and holds more than 1,000 publications in the biomedical field.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
